BiotechTube

Perflutren Lipid Microsphere Injectable Suspension

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Heart Disease

Trial Timeline

Apr 1, 2004 → Oct 1, 2012

NCT ID
NCT00162370

About Perflutren Lipid Microsphere Injectable Suspension

Perflutren Lipid Microsphere Injectable Suspension is a approved stage product being developed by Lantheus Holdings for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00162370. Target conditions include Coronary Artery Disease, Heart Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00162370ApprovedCompleted

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
ExenatideEli LillyPhase 3
77
Clopidogrel treatment groupYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
85
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
77
statins, ezetimibe + Combination therapyYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
85
clopidogrel + prasugrelDaiichi SankyoPhase 1
33
PrasugrelDaiichi SankyoApproved
85
ADP receptor inhibitorsDaiichi SankyoPre-clinical
23
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
52
prasugrel + clopidogrelDaiichi SankyoPhase 1
33
Prasugrel + ClopidogrelDaiichi SankyoApproved
85
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
77
Placebo + PrasugrelDaiichi SankyoPhase 3
77

Other Products from Lantheus Holdings

Piflufolastat F 18 Intravenous Solution [PYLARIFY]Approved
82
3D HI and SHI of UCAApproved
82
Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionApproved
82
DefinityApproved
82
Technetium Tc99m SestamibiApproved
82